GlobeNewswire·Dec 30, 2025, 8:00 AM ET

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

Collegium Pharmaceutical, Inc. closed its inaugural syndicated credit facility with an aggregate value of $980 million.
The facility matures in 2030 and consists of a $580 million initial Term Loan, a $300 million Delayed Draw Term Loan, & a $100 million revolving credit facility.
The initial Term Loan was used to repay the entire remaining balance of approximately $581 million from a previous term loan secured from Pharmakon Advisors, LP.
The undrawn Delayed Draw Term Loan & revolving credit facility are designated for general corporate purposes, including future business development opportunities.
Interest rates on the facility are based on SOFR plus a spread ranging from 2.75% to 3.75%, determined by the Company's First Lien Net Leverage Ratio.
The interest rate at closing was SOFR plus 2.75%, which is expected to generate meaningful annualized interest savings.
Truist Bank served as the administrative agent, while Truist Securities, Inc., Citizens Bank, N.A., MUFG Bank, Ltd., Fifth Third Bank, National Association, The Huntington National Bank, & U.S. Bank National Association acted as joint bookrunners & joint lead arrangers.
Flagstar Bank, N.A., PNC Bank, National Association, & Synovus Bank served as co-documentation agents for the syndicate.
Collegium plans to utilize the capital flexibility to expand & diversify its product portfolio, with Jornay PM identified as a key growth driver for its neuropsychiatry business.